X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
COVIFENZ, COVID-19 vaccine (plant-based virus-like particles [VLP], recombinant, adjuvanted), is indicated for active immunization to prevent coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 in individuals 18 to 64 years of age.
Lead Product(s): Recombinant Adjuvanted Plant-based Virus-like Particle
Therapeutic Area: Infections and Infectious Diseases Product Name: Covifenz
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
COVIFENZ® uses Coronavirus-Like Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs) co-administered with GSK’s pandemic adjuvant.
Lead Product(s): Recombinant Adjuvanted Plant-based Virus-like Particle
Therapeutic Area: Infections and Infectious Diseases Product Name: GSK4362620A
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2022
Details:
Apart from Canada regulatory filing has also been initiated for USFDA and MHRA for CoVLP (Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine), the first-ever plant-based vaccine, final portion of data submitted as part of New Drug Submission COVID rolling review.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: CoVLP
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2021
Details:
Covid19 Vaccine candidate demonstrated efficacy against all variants seen in the study, including 75.3% efficacy against COVID-19 of any severity caused by the globally dominant Delta variant.
Lead Product(s): CoVLP Adjuvanted Vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2021
Details:
The Phase 3 portion is an event-driven, randomized, observer-blinded, crossover placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation, compared to placebo, in up to 30,000 subjects.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: CoVLP
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2021
Details:
Medicago’s plant-derived vaccine candidate against COVID-19 uses Coronavirus-Like-Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) co-administered with GSK’s pandemic adjuvant.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: CoVLP
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
Details:
Anvisa said the companies were authorized to conduct phase 3 trials in the country. The companies are planning to test the new vaccines in around 30,000 people, in the U.S., Canada, Europe and Latin America. Brazil may have around 3,500 volunteers for the trials.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2021
Details:
Medicago's plant-derived vaccine candidate against COVID-19 uses Coronavirus-Like-Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) co-administered with GSK's pandemic adjuvant.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2021
Details:
The results of the trial demonstrated that 100 per cent of subjects developed a promising antibody response after two doses of Medicago’s COVID-19 adjuvanted vaccine candidate.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The Phase I clinical trial is a randomized, partially blinded study of 180 normal healthy subjects and will evaluate dosages of 3.75, 7.5 or 15 micrograms of the recombinant CoVLP vaccine candidate alone or with an adjuvant in a prime-boost regimen.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
